A retraction notice concerning research on S14G-humanin (HNG) was published on December 1, 2026. The notice, titled "Statement of Retraction: The protective effects of S14G-humanin (HNG) against mono-sodium urate (MSU) crystals-induced gouty arthritis," appeared in the journal Bioengineered.
The retraction applies to a prior publication examining S14G-humanin, a synthetic analog of the humanin peptide, in the context of gouty arthritis induced by mono-sodium urate crystals. This brief reports only that a retraction statement has been issued for the identified publication, as recorded in the event data.
No details beyond the retraction notice's title, journal, and publication date have been provided. The underlying reasons for the retraction, any corrections, or author responses are not included in the available information and are not reported here.
Humanin remains classified as an unapproved research compound. Readers should treat this update strictly as a record of a retraction notice and not as a statement about humanin's broader research findings or safety profile.
For additional background on this compound, readers can consult the compound overview.